Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2018, 27(5):242-248

Do gonadotropin-releasing hormone antagonists have a lower risk of cardiovascular complications in comparison to agonists?

Valášková Z1, Hulín I1, Fillo J2, El-Hassoun O3, Mladosievičová B1
1 Oddelenie klinickej patofyziológie LF UK v Bratislave
2 Urologická klinika LF UK a UNB, Bratislava
3 Ústav histológie a embryológie LF UK v Bratislave, Slovenská republika

Several studies have shown that the decreased testosterone levels in patients with prostate cancer who undergo androgen deprivation therapy with gonadotropin releasing hormone (GnRH) agonists can have increased risk of cardiovascular complications. The assumption that GnRH antagonists have a lower cardiovascular risk in comparison to agonists is not definitely demonstrated. It appears that therapy of hormone sensitive prostate cancer with GnRH antagonists is favourabe in patients with higher cardiovascular risk or a positive history of cardiovascular disease. This paper provides an update from clinical studies dealing with the cardiotoxicity of GnRH antagonists and agonists. Tab. 1, Ref. 41, on-line full text (Free, PDF) www. cardiologyletters.sk

Keywords: agonists GnRH; antagonists GnRH; cardiovascular risk; follicle-stimulating hormone; gonado­ tropin-releasing hormone

Published: May 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Valášková Z, Hulín I, Fillo J, El-Hassoun O, Mladosievičová B. Do gonadotropin-releasing hormone antagonists have a lower risk of cardiovascular complications in comparison to agonists? Cardiology Letters. 2018;27(5):242-248.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin 2010;60:194-201. Go to original source...
    2. Heidenreich A, Bastian PJ, Bellmunt J, et al. European Association of Urology: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467-479. Go to original source...
    3. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-4456. Go to original source...
    4. Smith MR. Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. Curr Urol Rep 2008;9:197. Go to original source...
    5. Klotz L, Miller K, Crawford ED, et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol 2014;66(6):1101-1108. Go to original source...
    6. Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 2014;65:565-573. Go to original source...
    7. Hopmans SN, Duivenvoorden WC, Werstuck GH, et al. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Urol Oncol 2014;32:1126-1134. Go to original source...
    8. Greiman AK, Keane TE. Approach to androgen deprivation in the prostate cancer patient with pre-existing cardiovascular disease. Curr Urol Rep 2017;18:41. Go to original source...
    9. Albertsen PC. Re: Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists. Eur J Cancer 2017;87:203. Go to original source...
    10. Shore ND, Abrahamsson PA, Anderson J, et al. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis 2013;16(1):715. Go to original source...
    11. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102(11):1531-1538. Go to original source...
    12. Tolkach Y, Joniau S, Van Poppel H. Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors? BJU Int 2013;111 (7):1021-1030. Go to original source...
    13. Poljak Z, Hulin I, Maruscakova L, et al. Are GnRH and FSH potentially damaging factors in the cardiovascular system? Pharmazie 2018;73(4):187-190. Go to original source...
    14. Scailteux LM, Naudet F, Alimi Q, et al. Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studies. Medicine (Baltimore) 2016;95:e3873. Go to original source...
    15. Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis. Eur Urol 2015;68:386-396. Go to original source...
    16. Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011;306:2359-2366. Go to original source...
    17. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:2420-2425. Go to original source...
    18. Wilcox C, Kautto A, Steigler A, et al. Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term. Oncology 2012;82:56-58. Go to original source...
    19. Kelly WK, Gomella LG. Androgen deprivation therapy and competing risks. JAMA2011;306:2382-2383. Go to original source...
    20. O'Farrell S, Garmo H, Holmberg L, et al. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2015;33:1243-1251. Go to original source...
    21. Keating N, O'Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease with androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102:39-46. Go to original source...
    22. Sun M, Choueiri TK, Hamnvik OP, et al. Comparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen deprivation therapy. JAMA Oncol 2016;2:500507. Go to original source...
    23. Chen DY, See LC, Liu JR, et al. Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study. J Clin Oncol 2017;35:3697-3705. Go to original source...
    24. Thomsen FB, Sandin F, Garmo H, et al. Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study. Eur Urol 2017;72:920-928. Go to original source...
    25. Smith MR, Klotz L, Persson BE, et al. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J Urol 2010;184:2313-2319. Go to original source...
    26. Smith MR, Klotz L, van der Meulen E, et al. Gonadotropinreleasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol 2011;186:1835-1842. Go to original source...
    27. Kimura T, Sasaki H, Akazawa K, et al. Gonadotropin-releasing hormone antagonist: A real advantage? Urol Oncol 2015;33:322-328. Go to original source...
    28. Nilsson J, Borre M, Bosnyak Z, et al. Association between baseline cardiovascular (CV) status and the development of CV events in prostate cancer (PCa) patients treated with luteinising hormonereleasing hormone (LHRH) agonist versus antagonist: Results of a pooled analysis. EAU 2015, Madrid Spain, Abstract 559. Go to original source...
    29. Scailteux LM, Naudet F, Alimi Q, et al. Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studies. Medicine (Baltimore) 2016;95:e3873. Go to original source...
    30. Scailteux LM. Response to letter - Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists. Eur J Cancer 2017;87:204. Go to original source...
    31. Margel D, Peer A, Ber Y, et al. Early cardiovascular morbidity in a pilot prospective randomized trial comparing LHRH agonist and antagonist among patients with advanced prostate cancer. J Urol 2017;197:Supple768. Go to original source...
    32. Tivesten Å, Pinthus JH, Clarke N, et al. Cardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms. Urol Oncol 2015; 33:464-475. Go to original source...
    33. Dong F, Skinner DC, Wu TJ, et al. The Heart: a novel gonadotrophinreleasing hormone target. J Neuroendocrinol 2011;23:456-463. Go to original source...
    34. Jespersen CG, Nørgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014;65:704-709. Go to original source...
    35. Xiaofei W, Xingqian Q, Tiantian Z, et al. Testosterone su­ppresses ventricular remodeling and improves left ventricular function in rats following myocardial infarction. J Am Coll Cardiol2014;64(16 Suppl C):C183. Go to original source...
    36. Knutsson A, Hsiung S, Celik S, et al. Treatment with an LHRH agonist, but not the LHRH antagonist degarelix, induces atherosclerotic plaque instability in ApoE-/- mice. EAU 2015, Madrid Spain, Abstract 558. Go to original source...
    37. Pickles T, Tyldesley S, Hamm J, et al. Brachytherapy for intermediate-risk prostate cancer, androgen deprivation, and the risk of death. Int J Radiat Oncol Biol Phys 2018;100:45-52. Go to original source...
    38. Wallis CJD, Satkunasivam R, Herschorn S, et al. Null association between androgen-deprivation therapy and nonprostate cancer mortality among older men with nonmetastatic prostate cancer. Urol Oncol 2018;36:241.e1-241.e6. Go to original source...
    39. Nguyen PL, D'Amico AV. Toward personalizing the use of androgen deprivation therapy to maximize benefit and minimize harm. Eur Urol 2015;68:397-398. Go to original source...
    40. Yang DD, Nguyen PL. Optimizing androgen deprivation therapy with radiation therapy for aggressive localized and locally advanced prostate cancer. Urol Oncol 2017, pii:S1078-1439(17)30557-4.
    41. A trial comparing cardiovascular safety of degarelix versus leuprolide in patients with advanced prostate cancer and cardiovascular disease - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02663908 [Accessed 12 October 2018].

    Return to the content